This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
What are the top 3 trends that defined pharma manufacturing in India and globally in 2024? In 2024, the pharmaceutical manufacturing landscape underwent transformative changes, driven by technological innovations, regulatory adaptations, and evolving global demands. Regulatory bodies in the U.S. and Europe.
Health Care Riders February 1, 2024 By: Allen Pinn, Coordinator, Policy In January, the Senate and House reached an agreement to fund the government through the first week of March. We reiterated these priorities to start the year in January 2024. The House passed H.R. 5378 More Transparency, Lower Costs Act in December 2023.
The time for commencing manufacturing or production was extended to 31 March 2024 by the Finance Act, 2022. Due to the multiplicity of regulatory processes and multiple regulators, undertaking operations become complex and time consuming. For pharma and medical devices policies, the Department of Pharmaceutical is the nodal agency. –
FDA is expected to provide initial feedback on the data submitted by July 2024, with further data to be collected and analysed over the next two years. How does the qualification package support more meaningful endpoints and rare disease research as a result?
The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. Similarly, updating the Explanation of Benefits to include visual aids and examples will clarify MPPP’s impact on cost-sharing and coverage.
The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. Similarly, updating the Explanation of Benefits to include visual aids and examples will clarify MPPP’s impact on cost-sharing and coverage.
NHC 2024 Policy Priorities December 13, 2023 By: Allen Pinn, Coordinator, Policy The National Health Council (NHC) prides itself in providing a voice for the over 160 million people living with a chronic disease or disability and their caregivers.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content